Outlook Therapeutics Inc
OTLK
Get informed when a big investor buys or sells
+ FollowMarket Cap$30.03M
Close$
$0.27
66.7% downside
Current Fair Value
66.7% downsideOvervalued by 66.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $30.03 Million |
|---|---|
| Enterprise Value | $-7,227,234,967,508.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.79 |
| Beta | 0.33 |
| Outstanding Shares | 81,836,000 |
Return
| Return on Equity | 130.71% |
|---|---|
| Return on Assets | -173.11% |
| Return on Invested Capital | 277.14% |
Valuation & Multiples
| P/E Ratio | -0.98 |
|---|---|
| PEG | 1.08 |
| Price to Sales | 0.0 |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | -4.69 |
| Enterprise Value to EBIT | 0.15 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.07 |
| Debt to Equity | -0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 21, 2026
EPS Estimate
$-0.12
Average shareholder expectationRevenue Estimate
$4.39 M
Average shareholder expectationNext Earnings Call
Expected Date
August 13, 2026
EPS Estimate
$-0.11
Average shareholder expectationRevenue Estimate
$5.08 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.6280▼ 397.23% |
|---|---|
| Total Calls | 246,800▼ 52.22% |
| Total Puts | 155,000▼ 93.48% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 17.82%▲ 6.49% |
|---|---|
| Total Invested | $2.21M▼ 79.53% |
| Investors Holding | 59▼ 2.00% |
ESG Score
No data
About Outlook Therapeutics Inc
8 employees
CEO: Lawrence Kenyon